“Company doesn’t talk about them for some reason”. I think you are well aware of those “some reason “ . One of them is obviously financial, which you have expertise to comment on so no need to say “some reason “. When they are struggling to fund tier1 products candidates Why would they focus their limited resources on these (Tier2) products candidates, priority kicks in isn’t it?
Cell Therapy News/Articles, page-122
-
- There are more pages in this discussion • 17,908 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.055(5.16%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | $1.00 | $1.607M | 1.574M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 103300 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 9026 | 5 |
View Market Depth
| Last trade - 11.40am 04/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |